Bausch+Lomb Results Presentation Deck
Reconciliation of Reported Revenue to Constant Currency Revenue¹ and
Constant Currency Revenue Growth¹ ($M)
Contact Lens
Consumer²
Surgical Consumables
Surgical Implantables
Surgical Equipment
Bausch+Lomb Ultra total
BioTrue ONEday Total
Artelac
Minims Total
BAUSCH + LOMB
1
2.
3.
4.
Calculation of Constant Currency Revenue for the Three Months Ended
March 31, 2023
March 31, 2022
Revenue as
Reported
226
361
95
44
44
51
52
30
15
Changes in
Exchange Rates³
10
10
3
2
1
1
1
1
1
Constant
Currency
Revenue (Non-
GAAP)¹
236
371
98
46
45
52
53
31
16
Revenue as
Reported
215
Amount
Pct.
11
5%
345
16
5%
26
87
8
9%
11
m
45
(1)
-2%
1
42
2
5%
44
7
16%
3
6%
6
25%
1
7%
49
24
Change in
Reported Revenue
14
Change in
Constant Currency Revenue
Amount
21
3
8
4
7
2
Pct.
10%
8%
13%
2%
7%
18%
8%
29%
14%
This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in
the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the
groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the
monthly average currency exchange rates during the comparable prior period.
As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their
respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.
29View entire presentation